Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy
Assembly Biosciences, Inc. (ASMB)
Last assembly biosciences, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.assemblybio.com/investor-relations
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that results from a research study evaluating the turnover rate of covalently closed circular DNA (cccDNA), which plays a pivotal role in the establishment and persistence of HBV infection, has been published in Hepatology, the journal of the American Association for the Study of Liver Diseases (AASLD). The study was led by Qi Huang, PhD, the Company’s Vice President of Virology Discovery, and was conducted in collaboration with Professors Jinlin Hou, Jian Sun, and Bin Zhou of Nanfang Hospital, Southern Medical University in Guangzhou, China. The article is entitled Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients and is available
Show less
Read more
Impact Snapshot
Event Time:
ASMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASMB alerts
High impacting Assembly Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ASMB
News
- Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent UpdatesGlobeNewswire
- Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366GlobeNewswire
- Assembly Biosciences, Inc. (NASDAQ: ASMB) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $2.00.MarketBeat
ASMB
Earnings
- 5/8/24 - Beat
ASMB
Sec Filings
- 11/19/24 - Form 4
- 11/14/24 - Form SC
- 11/7/24 - Form 8-K
- ASMB's page on the SEC website